Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia
Recruitment status was Not yet recruiting
Use Huperzine-A, a herbal supplement normally used for treatment of Alzheimer's disease, to potentially improve cognitive dysfunction (memory problems) and functional capacity (ability to perform common daily tasks such as cooking, bathing, telephone, shopping) in people with schizophrenia.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia|
- MATRICS Consensus Cognitive Battery [ Time Frame: First visit, 4 weeks, 8 weeks ] [ Designated as safety issue: No ]
- University of California Performance Skills Assessment-Brief (UPSA-B) [ Time Frame: First visit, 8 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||December 2009|
|Estimated Study Completion Date:||April 2011|
|Estimated Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Experimental: Huperzine A
200 micrograms (mcg) of HuperzineA taken twice daily.
Drug: Huperzine A
Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
HupA, an alkaloid initially identified from the Chinese herbal medicine Huperia serrata, is a potent reversible acetyl cholinesterase (AChE) inhibitor with additional unique properties including NMDA-receptor antagonist properties, neuroprotective and antioxidant effects. In animal studies, HupA was shown to possess greater inhibitory, longer-lasting, and more selective effects on AChE activity than donepezil. In clinical studies HupA improved memory, mood, and activities of daily living in patients with Alzheimer's dementia. Adverse effects have been reported at a very low rate in all the clinical trials, and are mainly cholinergic, such as dizziness, nausea, gastrointestinal symptoms, headaches and depressed heart rate. Thus, HupA is an attractive option which may have beneficial effects not only on cognitive but also functional domains of schizophrenia.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01012830
|Contact: Daniel A Ramirez, BS||800-451-5796 ext 4036||Daniel.Ramirez@va.gov|
|United States, Nebraska|
|Veterans Affairs Nebraska Western Iowa Health Care System||Not yet recruiting|
|Omaha, Nebraska, United States, 68105|
|Contact: Daniel A Ramirez, BS 800-451-5796 ext 4036 Daniel.Ramirez@va.gov|
|Principal Investigator: Prasad R Padala, MD, MS|
|Principal Investigator:||Prasad R Padala, MD, MS||VA Office of Research and Development|